We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much You'd Have If You Invested $1000 in Danaher a Decade Ago
Read MoreHide Full Article
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in Danaher (DHR - Free Report) ten years ago? It may not have been easy to hold on to DHR for all that time, but if you did, how much would your investment be worth today?
Danaher's Business In-Depth
With that in mind, let's take a look at Danaher's main business drivers.
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. It is headquartered in Washington, DC. The company’s segmental details are provided below:
Life Sciences (51.7% of revenues generated in first-quarter 2021) segment offers a broad range of research tools used to analyze a range of critical areas — including genes, proteins, metabolites and cells — to understand the causes of diseases, identify new therapies, and test new drugs and vaccines. Range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial.
Diagnostics (31.8%) segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps to diagnose diseases and take suitable treatment decisions.
Environmental & Applied Solutions(16.5%) segment offers products and services that help keep food and water supplies safe globally. Its instrumentation, software, consumables, services and disinfection systems helps analyze, treat and manage the quality of ultra-pure, potable, waste, ground, source and ocean water. Moreover, the product identification businesses develop and manufacture equipment, consumables and software for various printing, marking, coding, packaging, design and color-management applications.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Danaher, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in July 2011 would be worth $5,087.46, or a 408.75% gain, as of July 12, 2021, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
In comparison, the S&P 500 gained 225.16% and the price of gold went up 10.76% over the same time frame.
Going forward, analysts are expecting more upside for DHR.
In the past three months, Danaher’s shares have outperformed the industry. The company is poised to gain from the Danaher Business System (“DBS”), the policy of rewarding shareholders, buyouts and investment in product innovation in the quarters ahead. Recently, it agreed to acquire Aldevron. For second-quarter 2021, the company anticipates core revenue growth, including Cytiva, of a mid-20 percent range. The pandemic-led tailwinds are expected to boost core sales by low-double digits in the quarter. However, a rise in costs and expenses can be concerning for the company. Also, high debts raise financial obligations and international businesses as well as international operations have associated risks. In the past 60 days, the company's earnings estimates have been revised upward for 2021.
Shares have gained 12.33% over the past four weeks and there have been 2 higher earnings estimate revisions for fiscal 2021 compared to none lower. The consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Much You'd Have If You Invested $1000 in Danaher a Decade Ago
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in Danaher (DHR - Free Report) ten years ago? It may not have been easy to hold on to DHR for all that time, but if you did, how much would your investment be worth today?
Danaher's Business In-Depth
With that in mind, let's take a look at Danaher's main business drivers.
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. It is headquartered in Washington, DC. The company’s segmental details are provided below:
Life Sciences (51.7% of revenues generated in first-quarter 2021) segment offers a broad range of research tools used to analyze a range of critical areas — including genes, proteins, metabolites and cells — to understand the causes of diseases, identify new therapies, and test new drugs and vaccines. Range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial.
Diagnostics (31.8%) segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps to diagnose diseases and take suitable treatment decisions.
Environmental & Applied Solutions (16.5%) segment offers products and services that help keep food and water supplies safe globally. Its instrumentation, software, consumables, services and disinfection systems helps analyze, treat and manage the quality of ultra-pure, potable, waste, ground, source and ocean water. Moreover, the product identification businesses develop and manufacture equipment, consumables and software for various printing, marking, coding, packaging, design and color-management applications.
Bottom Line
Putting together a successful investment portfolio takes a combination of research, patience, and a little bit of risk. For Danaher, if you bought shares a decade ago, you're likely feeling really good about your investment today.
A $1000 investment made in July 2011 would be worth $5,087.46, or a 408.75% gain, as of July 12, 2021, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
In comparison, the S&P 500 gained 225.16% and the price of gold went up 10.76% over the same time frame.
Going forward, analysts are expecting more upside for DHR.
In the past three months, Danaher’s shares have outperformed the industry. The company is poised to gain from the Danaher Business System (“DBS”), the policy of rewarding shareholders, buyouts and investment in product innovation in the quarters ahead. Recently, it agreed to acquire Aldevron. For second-quarter 2021, the company anticipates core revenue growth, including Cytiva, of a mid-20 percent range. The pandemic-led tailwinds are expected to boost core sales by low-double digits in the quarter. However, a rise in costs and expenses can be concerning for the company. Also, high debts raise financial obligations and international businesses as well as international operations have associated risks. In the past 60 days, the company's earnings estimates have been revised upward for 2021.
Shares have gained 12.33% over the past four weeks and there have been 2 higher earnings estimate revisions for fiscal 2021 compared to none lower. The consensus estimate has moved up as well.